FrancophonIA/ELRC3.0 huggingface dataset:
English: Corrected for proportion of samples serotyped, missing age, denominator compared with 2009/10, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied).
Croatian: Ispravljeno prema udjelu serotipiziranih uzoraka, podacima o dobi koji nedostaju, denominatoru u usporedbi s 2009./10. i prema trendu u ukupnoj invazivnoj pneumokoknoj bolesti do 2009./10. (nakon čega više nije primijenjen ispravak trenda).
English: • has any bleeding problems or bruises easily.
Croatian: • imate poremećaj krvarenja ili Vam lako nastaju modrice.
English: Prevenar 13 is for intramuscular use only.
Croatian: Prevenar 13 je samo za intramuskularnu primjenu.
English: Skin and subcutaneous tissue disorders: Erythema multiforme
Croatian: Poremećaji kože i potkožnog tkiva: multiformni eritem
English: While direct cause-and-effect cannot be inferred from observational analyses of this type, these findings suggest that Prevenar plays an important role in reducing the burden of mucosal disease (AOM and pneumonia) in the target population.
Croatian: Iako se izravni uzročno-posljedični odnos ne može utvrditi na temelju ovakvih opažajnih ispitivanja, nalazi pokazuju da Prevenar igra važnu ulogu u smanjenju rasprostranjenosti bolesti sluznica (akutne upale srednjeg uha i upale pluća) u ciljnoj populaciji.
English: Table 5: Vaccine efficacy (VE) for the primary and secondary endpoints of the CAPiTA study (per protocol population)
Croatian: Tablica 5: Djelotvornost cjepiva (engl. vaccine efficacy, VE) za mjere primarnog i sekundarnih ishoda ispitivanja CAPiTA (u populaciji predviđenoj protokolom ispitivanja)
English: Prior to expelling air from the syringe, shake well to obtain a homogeneous white suspension.
Croatian: Prije istiskivanja zraka iz štrcaljke dobro protresite da se dobije homogena bijela suspenzija.
English: The efficacy of 7-valent Prevenar was evaluated in two major studies - the Northern California Kaiser Permanente (NCKP) study and the Finnish Otitis Media (FinOM) study.
Croatian: Djelotvornost 7-valentnog Prevenara bila je procijenjena u dva velika ispitivanja - ispitivanju Northern California Kaiser Permanente (NCKP) i finskom ispitivanje upale srednjeg uha (engl. the Finnish Otitis Media study - FinOM).
English: The duration of protective efficacy against a first episode of VT pneumococcal CAP, NB/NI VT pneumococcal CAP, and VT-IPD extended throughout the 4-year study.
Croatian: Trajanje djelotvornosti zaštite protiv prve epizode pneumokoknog VT-CAP-a, NB/NI pneumokoknog VT-CAP-a i VT-IPD-a obuhvatilo je cijelo 4-godišnje ispitivanje.
English: Other medicines/vaccines and Prevenar 13
Croatian: Drugi lijekovi/cjepiva i Prevenar 13
English: Table 4: Summary of effectiveness of 7-valent Prevenar for invasive pneumococcal disease Country (year of introduction)
Croatian: Tablica 4: Sažeti prikaz učinkovitosti 7-valentnog Prevenara protiv invazivne pneumokokne bolesti Zemlja (godina uvođenja cjepiva)
English: All serotypes: 73% Vaccine serotypes: 2-dose infant series: 99% Completed schedule:100%
Croatian: Svi serotipovi: 73% Serotipovi cjepiva: Serija s 2 doze za dojenčad: 99% završeno cijepljenje:100%
English: Tell your doctor, pharmacist or nurse if you have been given a pneumococcal vaccine before.
Croatian: Obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako ste prije dobili pneumokokno cjepivo.
English: As with concomitant administration with trivalent vaccines, immune responses to some pneumococcal serotypes were lower when both vaccines were given concomitantly.
Croatian: Kao i kod istodobne primjene s trovalentnim cjepivima, imunološki odgovori na neke serotipove pneumokoka bili su niži kada su oba cjepiva primijenjena istodobno.
English: Adverse reactions reported in clinical studies or from the postmarketing experience for all age groups are listed in this section per system organ class, in decreasing order of frequency and seriousness.
Croatian: Nuspojave zabilježene u kliničkim ispitivanjima ili nakon stavljanja cjepiva u promet za sve dobne skupine navedene su u ovom dijelu prema klasifikaciji organskih sustava i slijedom prema sve manjoj učestalosti i ozbiljnosti.
English: Since the introduction of 7-valent Prevenar in 2000, pneumococcal disease surveillance data have not shown that the immunity elicited by Prevenar in infancy has waned over time.
Croatian: Otkad je 2000. godine uveden 7-valentni Prevenar, podaci praćenja pneumokokne bolesti nisu pokazali da imunitet potaknut Prevenarom u dojenačkoj dobi slabi tijekom vremena.
English: Pack of 1, 10 and 50 pre-filled syringe, with or without needle - WITH BLUE BOX
Croatian: Pakiranje od 1, 10 i 50 napunjenih štrcaljki, s ili bez igle - S PLAVIM OKVIROM
English: In a similar analysis, hospitalisations and ambulatory visits for all-cause pneumonia were reduced by 52.4 % and 41.1 %, respectively.
Croatian: U sličnoj analizi, broj hospitalizacija zbog upale pluća svih uzroka bio je smanjen za 52,4 % , a ambulantnih posjeta za 41,1 %.
English: It is unknown whether immunological memory to all serotypes is induced in pre-term infants.
Croatian: Nije poznato stvara li se u prijevremeno rođene dojenčadi imunološka memorija na sve serotipove.
English: Children younger than 2 years old should receive the appropriate-for-age Prevenar 13 vaccination series (see section 4.2).
Croatian: Djeca mlađa od 2 godine morala bi primiti seriju cjepiva Prevenar 13 odgovarajuću za svoju dob (vidjeti dio 4.2).
English: The safety of the vaccine was assessed in controlled clinical studies where 14,267 doses were given to 4,429 healthy infants from 6 weeks of age at first vaccination and 11-16 months of age at booster dose.
Croatian: Sigurnost cjepiva procijenjena je u kontroliranim kliničkim ispitivanjima u kojima je primijenjeno 14 267 doza u 4429 zdrave dojenčadi u dobi od 6 tjedana pri prvom cijepljenju i 11 do 16 mjeseci pri docjepljivanju.
English: In an open-label study in 592 healthy children and adolescents including those with asthma (17.4%) who may be predisposed to pneumococcal infection, Prevenar 13 elicited immune responses to all 13 serotypes.
Croatian: U otvorenom ispitivanju 592 zdrave djece i adolescenata uključujući one s astmom (17,4 %) koji su vjerojatno bili predodređeni za pneumokoknu infekciju, Prevenar 13 je aktivirao imunološki odgovor na svih 13 serotipova.
English: NNV is not a rate but instead indicates the number of cases prevented for a given number of persons vaccinated.
Croatian: Broj potrebnih cijepljenja nije stopa, već pokazuje broj spriječenih slučajeva na određeni broj cijepljenih osoba.
English: The CAPiTA study enrolled volunteers ≥ 65 years of age whose demographic and health characteristics may differ from those seeking vaccination.
Croatian: ≥ 65 godina čija se demografija i zdravstvene karakteristike mogu razlikovati od onih koji traže cjepivo.
English: For 9 serotypes, immune responses were related to age, with adults in the 50-59 years group showing statistically significantly greater responses than adults aged 60-64 years.
Croatian: Za 9 serotipova, imunološki odgovor bio je povezan s dobi, jer su odrasli u dobi od 50 do 59 godina imali statistički značajno veće odgovore nego odrasli u dobi od 60 do 64 godine.
English: Confidence intervals (CIs) for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures.
Croatian: Intervali pouzdanosti (CI) za omjer povratne su transformacije intervala pouzdanosti temeljenog na studentovoj t distribuciji za geometrijsku sredinu razlike logaritama mjera.
English: Individuals with impaired immune responsiveness, whether due to the use of immuno-suppressive therapy, a genetic defect, human immunodeficiency virus (HIV) infection, or other causes, may have reduced antibody response to active immunisation.
Croatian: Osobe s narušenim odgovorom imunološkog sustava, bilo zbog imunosupresivne terapije, genetskog oštećenja, infekcije virusom humane imunodeficijencije (HIV) ili drugih uzroka, mogu imati slabiji odgovor protutijela na aktivnu imunizaciju.
English: Vaccine serotypes: 98% All serotypes: 77%
Croatian: Serotipovi cjepiva: 98% Svi serotipovi: 77%
English: Safety was evaluated in 592 children (294 children aged 5 to 10 years previously immunised with at least one dose of Prevenar and 298 children aged 10 to 17 years who had not received a pneumococcal vaccine).
Croatian: Sigurnost se procjenjivala kod 592 djece (294 djece u dobi od 5 do 10 godina koja su prethodno bila imunizirana najmanje jednom dozom Prevenara i kod 298 djece u dobi od 10 do 17 godina koja nisu primila pneumokokno cjepivo).
English: Suspension for injection in multidose container (4 doses).
Croatian: Suspenzija za injekciju u višedoznom spremniku (4 doze).
English: Prevenar (7-valent) effectiveness
Croatian: Učinkovitost Prevenara (7-valentnog)
English: The efficacy results from these studies (for invasive pneumococcal disease, pneumonia, and acute otitis media) are presented below (Table 3).
Croatian: Rezultati ovih ispitivanja u pogledu djelotvornosti (protiv invazivne pneumokokne bolesti, upale pluća i akutne upale srednjeg uha) prikazani su niže (tablica 3).
English: Vaccine serotypes: 76% All serotypes: 38%
Croatian: Serotipovi cjepiva: 76% Svi serotipovi: 38%
English: Prevenar 13 elicited functional antibodies to all 13 vaccine serotypes in studies 004 and 006.
Croatian: Prevenar 13 izazvao je stvaranje funkcionalnih protutijela protiv svih 13 serotipova cjepiva u ispitivanjima 004 i 006.
English: However, some of the effects mentioned under section 4.8 “Undesirable effects” may temporarily affect the ability to drive or use machines.
Croatian: Međutim, neki od učinaka spomenutih u dijelu 4.8 „Nuspojave“ mogu privremeno utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: Approximately one month after the toddler dose, the proportion of subjects in each group achieving this same antibody concentration threshold was >97%, except for serotype 3 (71% in preterm infants and 79% in term infants).
Croatian: Otprilike mjesec dana nakon doze za malu djecu, udio ispitanika u svakoj skupini koji su postigli ovu istu graničnu vrijednost koncentracije protutijela bio je >97%, osim za serotip 3 (71% u prijevremeno rođene dojenčadi i 79% u dojenčadi rođene u terminu).
English: Reductions were 53% (167 to 79 cases) (p<0.001) for CAP cases with pleural effusion and 63% (64 to 24 cases) (p<0.001) for microbiologically confirmed pneumococcal CAP cases.
Croatian: Smanjenja su bila 53% (167 do 79 slučajeva) (p<0,001) za izvanbolničke slučajeve upale pluća s pleuralnom efuzijom i 63% (64 do 24 slučajeva) (p<0,001) za mikrobiološki potvrđene slučajeve pneumokoknih izvanbolničkih slučajeva upala pluća.
English: Prevenar 13 immunogenicity clinical studies in infants, children and adolescents
Croatian: Klinička ispitivanja imunogenosti Prevenara 13 u dojenčadi, djece i adolescenata
English: 2, 4, 6, + 12-15 months
Croatian: 2, 4, 6, + 12-15 mjeseci
English: For the six additional serotypes, these values were compared with the lowest response among all of the seven common serotypes in the Prevenar recipients.
Croatian: Za šest dodatnih serotipova, te su vrijednosti bile uspoređene s najslabijim odgovorom na neki od sedam čestih serotipova u primatelja Prevenara.
English: The most common adverse events in children and adolescents 6 to 17 years of age were:
Croatian: Najčešći štetni događaji kod djece i adolescenata u dobi od 6 do 17 godina bili su:
English: Subcutaneous administration of Prevenar 13 was evaluated in a non-comparative study in 185 healthy Japanese infants and children who received 4 doses at 2, 4, 6 and 12-15 months of age.
Croatian: Supkutana primjena Prevenara 13 bila je procijenjena u nekomparativnom ispitivanju u 185 zdrave dojenčadi i djece u Japanu koja su primila 4 doze u dobi od 2, 4, 6 i 12-15 mjeseci.
English: Immune system disorders: Anaphylactic/anaphylactoid reaction including shock; angioedema
Croatian: Poremećaji imunološkog sustava: anafilaktička/anafilaktoidna reakcija uključujući šok; angioedem
English: * Patients with at least 2 of the following: Cough; purulent sputum, temperature >38°C or <36.1°C; pneumonia (auscultatory findings); leukocytosis; C-reactive protein value >3 times the upper limit of normal; hypoxemia with a partial oxygen pressure <60 mm Hg while breathing room air.
Croatian: * Bolesnici s najmanje 2 sljedeća stanja: kašalj; gnojni iskašljaj, temperatura > 38 °C ili < 36,1 °C; upala pluća (auskultacijski nalaz); leukocitoza; vrijednost C-reaktivnog proteina > 3 puta iznad gornje granice normalne vrijednosti; hipoksemija s parcijalnim tlakom kisika < 60 mm Hg prilikom udisanja sobnog zraka.
English: In addition, OPA GMTs between subjects receiving Prevenar 13 with or without 2-PE were compared.
Croatian: Pored toga, uspoređeni su OPA GMT-ovi između ispitanika koji primaju Prevenar 13 sa ili bez 2-PE.
English: Alternatively, when Prevenar 13 is given as part of a routine infant immunisation programme, a series consisting of three doses, each of 0.5 ml, may be given.
Croatian: Alternativno, kad se Prevenar 13 daje u sklopu rutinskog programa imunizacije dojenčadi, može se dati serija od tri doze, svaka po 0,5 ml.
English: Studies of Prevenar 13 not containing the preservative 2-PE
Croatian: Ispitivanja Prevenara 13 koji ne sadrži 2-PE
English: Lymphadenopathy localized to the region of the vaccination-site
Croatian: limfadenopatija lokalizirana na regiju mjesta primjene injekcije
English: Multidose containers:
Croatian: Višedozni spremnici:
English: The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults.
Croatian: Najpogodnija mjesta su anterolateralna strana bedra (musculus vastus lateralis) u dojenčadi i deltoidni mišić nadlaktice u djece i odraslih.
English: Study of Prevenar 13 containing the preservative 2-phenoxyethanol (2-PE):
Croatian: Ispitivanje lijeka Prevenar 13 koji sadrži konzervans 2-fenoksietanol (2-PE):
English: Vomiting (in adults aged 50 years and over)
Croatian: povraćanje (u odraslih u dobi od 50 i više godina)
English: Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, or to diphtheria toxoid.
Croatian: Preosjetljivost na djelatne tvari, neku od pomoćnih tvari navedenih u dijelu 6.1 ili toksoid difterije.
English: • Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing
Croatian: • alergijska reakcija (reakcija preosjetljivosti), uključujući otečenost lica i/ili usana, otežano disanje
English: In all infant studies, Prevenar 13 was co-administered with routine paediatric vaccines (see section 4.5).
Croatian: U svim ispitivanjima u dojenčadi, Prevenar 13 primjenjivao se istodobno s cjepivima koja se rutinski primjenjuju u pedijatrijske populacije (vidjeti dio 4.5).
English: Unvaccinated infants, children, and adolescents over 7 months of age
Croatian: Necijepljena dojenčad, djeca i adolescenti u dobi iznad 7 mjeseci
English: Five clinical studies were conducted in Europe and the USA evaluating the immunogenicity of Prevenar 13 in different age groups ranging from 18-95 years of age.
Croatian: Pet kliničkih ispitivanja bilo je provedeno u Europi i SAD-u radi procjene imunogenosti Prevenara 13 u različitim dobnim skupinama u dobnom rasponu od 18-95 godina.
English: A trend to lower frequency of adverse reactions was associated with greater age; adults > 65 years of age (regardless of prior pneumococcal vaccination status) reported fewer adverse reactions than younger adults, with adverse reactions generally most common in the youngest adults, 18 to 29 years of age.
Croatian: Trend smanjivanja učestalosti nuspojava povezuje se s porastom dobi; odrasli >65 godina starosti (bez obzira na prethodni cjepni status protiv pneumokoka) prijavili su manje nuspojava nego mlađe odrasle osobe, a najčešće nuspojave općenito su se javile u najmlađih odraslih osoba, u dobi od 18 do 29 godina.
English: No data are currently available regarding concomitant use with other vaccines.
Croatian: Trenutno nema dostupnih podataka u vezi istodobne primjene s drugim cjepivima.
English: Limited data have demonstrated that Prevenar 7-valent (three-dose primary series) induces an acceptable immune response in infants with sickle cell disease with a safety profile similar to that observed in non-high-risk groups (see section 5.1).
Croatian: Ograničeni podaci pokazuju da 7-valentni Prevenar (primarna serija od tri doze) izaziva prihvatljiv imunološki odgovor u dojenčadi s anemijom srpastih stanica uz sigurnosni profil sličan onome opaženom u skupinama koje nemaju visoki rizik (vidjeti dio 5.1).
English: Overall, the frequency categories were similar for all age groups, with the exception of vomiting which was very common ( 1/10) in adults aged 18 to 49 years and common ( 1/100 to < 1/10) in all other age groups, and pyrexia was very common in adults aged 18 to 29 years and common in all other age groups.
Croatian: Općenito, kategorije učestalosti bile su slične u svim dobnim skupinama, s iznimkom povraćanja koje je bilo vrlo često ( 1/10) u odraslih u dobi od 18 do 49 godina i često ( 1/100 i < 1/10) u svim ostalim dobnim skupinama, a vrućica je bila vrlo česta u odraslih u dobi od 18 do 29 godina i česta u svim ostalim dobnim skupinama.
English: • Vomiting (for those 50 years and older); fever (for those 30 years and older)
Croatian: • povraćanje (u dobi od 50 i više godina); vrućica (u dobi od 30 i više godina)
English: Efficacy against vaccine-type (VT) pneumococcal CAP and IPD was assessed in a large-scale randomised double-blind, placebo-controlled study (Community-Acquired Pneumonia Immunization Trial in Adults-CAPiTA) in the Netherlands.
Croatian: Djelotvornost protiv CAP-a i IPD-a uzrokovanih pneumokokom vrste koja je prisutna u cjepivu (engl. vaccine-type, VT) procijenjena je u velikom randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju (Community-Acquired Pneumonia Immunization Trial in Adults-CAPiTA) u Nizozemskoj.
English: The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born  28 weeks of gestation), and particularly for those with a previous history of respiratory immaturity.
Croatian: Potrebno je razmotriti mogućnost rizika od apneje i potrebu za praćenjem disanja tijekom 48-72 sata kad se provodi primarna imunizacija dojenčadi koja je bila vrlo rano rođena (rođenih nakon ≤ 28 tjedana gestacije), a osobito one s nezrelošću dišnog sustava u povijesti bolesti.
English: Talk to your doctor, pharmacist, or nurse before the vaccination if your child was born very prematurely (at or before 28 weeks of gestation), as longer gaps than normal between breaths may occur for 2-3 days after vaccination.
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije cijepljenja ako je Vaše dijete rođeno prerano (u 28. ili prije 28. tjedna trudnoće) jer dva do tri dana poslije cijepljenja stanke između udisaja mogu biti dulje no obično.
English: 2, 4, + 12 months
Croatian: 2, 4, + 12 mjeseci
English: The vaccine should be given by intramuscular injection.
Croatian: Cjepivo se primjenjuje intramuskularnom injekcijom.
English: Additionally, all 13 serotypes met the pre-defined non-inferiority criterion for IgG GMCs (lower bound of the 97.5% CI of GMC ratio [GMR] was greater than 0.5).
Croatian: Pored toga, svih 13 serotipova ispunjavalo je unaprijed definiranu mjeru neinferiornosti za IgG GMC-ove (donja granica od 97,5% CI GMC omjera [GMR] bila je veća od 0,5).
English: 84,496 subjects, 65 years and older received a single vaccination of either Prevenar 13 or placebo in a 1:1 randomisation.
Croatian: 84 496 ispitanika u dobi od 65 i više godina dobilo je jednokratnu dozu cjepiva Prevenar 13 ili placeba u randomizaciji 1:1.
English: The interval between the 13-valent pneumococcal conjugate vaccine (Prevenar 13) and the 23-valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Croatian: Vremenski razmak između 13-valentnog pneumokoknog konjugiranog cjepiva (Prevenar 13) i 23-valentnog pneumokoknog polisaharidnog cjepiva ne smije biti manji od 8 tjedana.
English: In this study, reductions of S. pneumoniae serotypes 19A, 19F, and 6A not susceptible to a number of antibiotics were documented.
Croatian: U ovom ispitivanju zabilježeno je smanjenje serotipova S. pneumoniae 19A, 19F i 6A koji nisu osjetljivi na više antibiotika.
English: Therefore the use of Prevenar 13 should be avoided during pregnancy.
Croatian: Stoga primjenu Prevenara 13 treba izbjegavati tijekom trudnoće.
English: This dose of Prevenar 13 should be administered at least 8 weeks after the final dose of Prevenar (7-valent) (see section 5.1).
Croatian: Tu dozu Prevenara 13 treba primijeniti najmanje 8 tjedana nakon zadnje doze Prevenara (7-valentnog) (vidjeti dio 5.1).
English: Effect on nasopharyngeal carriage
Croatian: Učinak na nazofaringealno kliconoštvo
English: First episode of confirmed VT pneumococcal CAP
Croatian: Prva epizoda potvrđenog pneumokoknog VT-CAP-a
English: Immune responses were assessed in 259-270 evaluable subjects approximately 1 month after each dose of vaccine.
Croatian: Imunološki su odgovori procijenjeni kod 259-270 ispitanika kod kojih se on mogao ocijeniti približno mjesec dana nakon svake doze cjepiva.
English: In the same study another group of adults aged 50-59 years and another group of adults aged 18-49 years received a single dose of Prevenar 13.
Croatian: U istom je ispitivanju druga skupina odraslih u dobi od 50 do 59 godina i još jedna skupina odraslih u dobi od 18 do 49 godina primila jednu dozu Prevenara 13.
English: In general, adverse events reported with overdose are consistent with those that have been reported with doses given in the recommended paediatric schedules of Prevenar 13.
Croatian: Općenito su nuspojave zabilježene kod predoziranja sukladne onima koje su zabilježene uz doze koje se daju prema preporučenom pedijatrijskom rasporedu za Prevenar 13.
English: Based on serotype surveillance in Europe performed before the introduction of Prevenar, Prevenar 13 is estimated to cover 73-100% (depending on the country) of serotypes causing invasive pneumococcal disease (IPD) in children less than 5 years of age.
Croatian: Na temelju praćenja serotipova u Europi provedenom prije uvođenja Prevenara, procjenjuje se da Prevenar 13 pokriva 73-100 % (ovisno o zemlji) serotipova koji uzrokuju invazivnu pneumokoknu bolest u djece mlađe od 5 godina.
English: S. pneumoniae is one of the most common causes of bacterial AOM worldwide.
Croatian: S. pneumoniae jedan je od najčešćih uzročnika bakterijske akutne upale srednjeg uha u svijetu.
English: Unvaccinated infants and children ≥ 7 months of age
Croatian: Necijepljena dojenčad i djeca ≥ 7 mjeseci
English: Do not use this medicine after the expiry date which is stated on the carton and label after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici nakon oznake „Rok valjanosti“/EXP.
English: Unvaccinated Children (12-23 months)
Croatian: Necijepljena djeca (u dobi od 12 mjeseci do 23 mjeseca)
English: Prevenar OPA GMT Relative to PPSV23
Croatian: OPA GMT Prevenara u odnosu na PPSV23
English: As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
Croatian: Kao i kod svih cjepiva koja se injiciraju, potrebno je osigurati dostupnost odgovarajuće medicinske skrbi i nadzora zbog rijetkih slučajeva anafilaktičke reakcije nakon primjene cjepiva.
English: There are no data from the use of pneumococcal 13-valent conjugate vaccine in pregnant women.
Croatian: Nema podataka o primjeni pneumokoknog 13-valentnog konjugiranog cjepiva u trudnica.
English: ≥65 years of age
Croatian: ≥65 godina